FDA Reduces Monitoring Time for Initial Doses of Amgen's IMDELLTRA for Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen's IMDELLTRA® (tarlatamab-dlle), significantly reducing the recommended monitoring time for the first two doses of treatment. Patients receiving IMDELLTRA for extensive-stage small cell lung cancer (ES-SCLC) will now require 6 to 8 hours of monitoring, down from the previous 22 to 24 hours, followed by a day-after assessment. This change aims to simplify care, reduce time spent in healthcare settings, and potentially increase access to treatment in community oncology practices.